SkinBioTherapeutics plc (AIM:SBTX)

London flag London · Delayed Price · Currency is GBP · Price in GBX
8.00
+0.15 (1.91%)
At close: Mar 25, 2026
Market Cap20.73M -63.5%
Revenue (ttm)4.64M +283.7%
Net Income-696.25K
EPS-0.00
Shares Out259.17M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,592,787
Average Volume2,777,347
Open7.85
Previous Close7.85
Day's Range7.50 - 8.40
52-Week Range5.00 - 27.50
Beta0.47
RSI39.90
Earnings DateApr 1, 2026

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 41
Stock Exchange London Stock Exchange AIM
Ticker Symbol SBTX
Full Company Profile

Financial Performance

In fiscal year 2025, SkinBioTherapeutics's revenue was 4.64 million, an increase of 283.74% compared to the previous year's 1.21 million. Losses were -696,253, -75.79% less than in 2024.

Financial Statements